ReviewExperimental hematology2015
Novel therapeutic strategies for multiple myeloma.
Review in Experimental hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.BioMed research international · 2018Pooled it
- Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates.JCO clinical cancer informatics · 2017Pooled it
- Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.Frontiers in medicine · 2026Review
- Review
- The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.Cancer research · 2025Article
- A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.Molecular and cellular biochemistry · 2024Article
- Current and Future PET Imaging for Multiple Myeloma.Life (Basel, Switzerland) · 2023Review
- The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.Cancer immunology, immunotherapy : CII · 2023Article
- Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.Leukemia · 2023Article
- The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3β in myeloma by atypical K63-linked polyubiquitination.The Journal of biological chemistry · 2023Article
- Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma.Frontiers in oncology · 2023Review
- [Diagnostic and prognostic value of serum miR-19a-3p in patients with multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway.Experimental and therapeutic medicine · 2022Article
- Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a.The Kaohsiung journal of medical sciences · 2022Article
- Evaluating the role of propolis and bee venom on the oxidative stress induced by gamma rays in rats.Scientific reports · 2022Article
- Identification of candidate targets and mechanisms involved in miRNA regulation in multiple myeloma.World journal of surgical oncology · 2022Article
- Multiple myeloma metabolism - a treasure trove of therapeutic targets?Frontiers in immunology · 2022Review
- HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs.PloS one · 2022Article
- Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells.Stem cells international · 2022Article
- Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma.Frontiers in oncology · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Multiple myeloma (MM) is a plasma-cell malignancy which remains incurable despite the recent emergence of multiple novel agents. Importantly, recent genetic and molecular analyses have revealed the complexity and heterogeneity of this disease, highlighting the need for therapeutic strategies to eliminate all clones. Moreover, the bone marrow microenvironment, including stromal cells and immune cells, plays a central role in MM pathogenesis, promoting tumor cell growth, survival, and drug resistance. New classes of agents including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors have shown remarkable efficacy; however, novel therapeutic approaches are still urgently needed to further improve patient outcomes. In this review, we discuss the recent advances and future strategies to ultimately develop MM therapies with curative potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.